Financial Data and Key Metrics Changes - Total expenses increased by $396,000 quarter over quarter to $2,700,000 in Q1 2025 compared to $2,300,000 in Q1 2024 [14] - Research and development expenses rose by $289,000 to $1,500,000 in Q1 2025 from $1,200,000 in Q1 2024, driven by costs related to the cardiac heart failure trial [15] - Net loss was $2,700,000 in Q1 2025 compared to $2,300,000 in Q1 2024 [16] Business Line Data and Key Metrics Changes - The CARDI Amp heart failure trial results showed safety and meaningful benefits for heart failure patients, with a focus on sharing data with regulatory agencies [5] - The CardioM Heart Failure II trial is actively enrolling patients at three clinical sites, with expectations for full enrollment over the next two years [6] - The Helix biotherapeutics delivery system is preparing for submission for approval, with potential value for therapeutic partners [7] Market Data and Key Metrics Changes - The electrophysiology market, valued at over $10 billion annually, is expanding to treat arrhythmias in the ventricles of the heart, where the company delivers cell therapies [11] - The company is focused on the Japanese market, with ongoing discussions with regulators and potential distributors for the CARDI Amp cell therapy [25] Company Strategy and Development Direction - The company aims to align with the FDA and Japan's PMDA to make the CARDI Amp therapy available to physicians and patients [5] - The strategy includes enhancing partnerships across all four platforms: CardiAmp, Cardiallo, Helix, and MorphDNA, to create value for shareholders [10] - The company is focused on minimizing operational costs and enhancing enrollment through partnerships and innovative delivery systems [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the approval process in Japan, anticipating a six-month timeframe for clarity on submission [30] - The company believes that its extensive clinical data will help close the valuation gap with peers in Japan [33] - Management highlighted the importance of ongoing clinical trials to develop further evidence for their therapies [38] Other Important Information - The company completed a small financing with minimal dilution to support upcoming milestones [13] - The company maintains a low burn rate, providing flexibility in funding value creation [16] Q&A Session Summary Question: Discussion on business development maturity - Management emphasized the importance of established products and ongoing discussions with large strategic partners [20] Question: Importance of Japan's PMDA submission - Management confirmed that PMDA's acceptance for submission is akin to FDA's acceptance of a BLA, which is critical for market entry [28] Question: Interaction between ongoing trials and FDA submission - Management clarified that they are developing additional evidence while submitting for FDA approval, focusing on patient enrollment and trial design improvements [39]

Financial Data and Key Metrics Changes - The cash operating expenses for Q1 2025 totaled $2.9 million, a decrease from $4.2 million in Q1 2024, indicating a reduction in personnel and general administrative expenses [17][18] - The company has adjusted its 2025 expected cash operating expense guidance to a range of $17 million to $19 million [17] Business Line Data and Key Metrics Changes - The nephro CRRT trial has seen a reduction in study size from 166 patients to 70 patients, which is expected to shorten the study completion time [4][5] - The company has added three new clinical study sites that are actively screening patients, with five more expected by mid-year [6][12] Market Data and Key Metrics Changes - There is an ongoing inquiry from healthcare providers regarding the availability of Nefamostat due to shortages of citrate and potential supply chain issues with heparin [7] Company Strategy and Development Direction - The company is focused on completing the nephro study by the end of 2025 and believes that the new site engagement will significantly contribute to study enrollment [11][15] - The company is exploring a compassionate use IDE for Nefamostat, responding to requests from institutions for patients who do not respond well to current anticoagulants [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the low clinical, regulatory, and commercial risks associated with the nephro program, citing a strong track record of nafamostat's efficacy and safety [15] - The company anticipates that the expanded enrollment criteria will lead to increased activity at both legacy and new sites, although immediate results from legacy sites have not yet materialized [24][30] Other Important Information - The company completed a PIPE financing structured in three tranches, with the first tranche received and the remaining tranches contingent on patient enrollment milestones [19] Q&A Session Summary Question: Has the broader enrollment criteria started to translate into increased enrollment? - Management noted that while there has been increased activity at the sites due to broader criteria, it has not yet translated into new patients from legacy sites [24][25] Question: What are the challenges faced by legacy sites in enrolling patients? - The legacy sites are primarily dependent on surgical ICUs or cardiothoracic ICUs, which limits their patient pool despite the expanded criteria [29]

Financial Data and Key Metrics Changes - The company reported revenues of $20.1 million for Q1 2025, a 42.5% increase compared to $14.1 million in Q1 2024 [5][20] - Bookings increased by 13.6% to $22.2 million compared to $19.6 million in the same period last year [22] - The net loss for Q1 2025 was $1.9 million, slightly higher than the loss of $1.8 million in Q1 2024 [21] - EBITDA for the quarter was a loss of $3.2 million, compared to a loss of $1.9 million in the prior year [22] Business Line Data and Key Metrics Changes - Total units sold increased by 45% to 1.5 million, primarily driven by the flagship ARC franchise [5] - The mobile segment saw significant growth, with ARC Ultimate Mobile Edition achieving 4.8 million downloads and an average daily active user count of approximately 144,000 [7][20] Market Data and Key Metrics Changes - PC gaming accounted for approximately 48% of revenue in 2024, compared to 41% from consoles [24] - The company noted that the mobile game segment helps offset broader economic impacts, as it lowers the barriers to entry for new players [24] Company Strategy and Development Direction - The company is focused on expanding its content portfolio and diversifying revenue streams, including a new short drama business [10][19] - Upcoming releases and announcements are planned to celebrate the ten-year anniversary of the ARC franchise, with a focus on engaging a broader audience [26] - The company aims to invest in scalable growth opportunities across adjacent genres and emerging platforms [26] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the impact of tariffs on the business, noting that while direct impacts are limited, indirect effects could influence consumer spending [23][25] - The gaming industry has historically shown resilience in the face of economic uncertainty, and the company remains confident in its ability to adapt [25] Other Important Information - The company has signed an MOU with MacMetrix Inc. to co-develop at least 10 short drama series over the next twelve months [10][34] - The company is actively exploring new business opportunities and expanding its indie publishing label, Wandering Wizard [19] Q&A Session Summary Question: Can you discuss your approach to revenue diversification? - The company is exploring and investing in new games and businesses, including a short drama initiative and several new game releases [28][30] Question: What are the revenue implications of the MOU with Mega Matrix? - It is too early to measure potential revenue contributions, but the MOU involves co-developing at least 10 drama series over the next year [31][34] Question: Can you elaborate on the increase in advertising and marketing costs? - Marketing expenditures have increased due to a larger portfolio and participation in events like GDC, but the company does not expect such increases to continue in the upcoming quarters [36][38] Question: How should investors view the approach to achieving positive net income? - The company focuses on cost control and diversified monetization strategies, including outsourcing development and expanding into new revenue streams [39][40]

Financial Data and Key Metrics Changes - Revenue for the first quarter of 2025 was $23.8 million, up from $20.2 million in the fourth quarter and $18.3 million in the prior year period, reflecting a 30% year-over-year growth [26][27] - Operating EBITDA increased to $12.3 million for the first quarter, compared to $10.7 million in the prior year period, primarily due to the NJR acquisition [28][29] - The company reported a GAAP net loss attributable to stockholders of $15.3 million [28] Business Line Data and Key Metrics Changes - The acquisition of rooftop assets from NJR positively impacted revenue and operating EBITDA, with the company owning and operating approximately 85,000 home solar assets and servicing around 60,000 residential solar systems [5][6] - Portfolio O&M expenses were $3.9 million in the first quarter, down from $5.3 million in the fourth quarter, indicating a sequential decline of over 25% [27] - SG&A expenses were $14.1 million in the first quarter, down from $15.5 million in the fourth quarter but up from $13.5 million in the prior year period [27] Market Data and Key Metrics Changes - The company is experiencing a cautious approach to new growth opportunities due to uncertainty in the market, which has affected cash burn and revenue collection timing [7][29] - The New Jersey market has deep liquidity in the SREC market, which is expected to continue supporting revenue generation [39] Company Strategy and Development Direction - The company aims to achieve positive free cash flow through growth in solar installations, prudent cost containment, and disciplined acquisition strategies [6][11] - Spruce Pro is identified as a key revenue driver, leveraging existing infrastructure to provide services to third-party owners of solar assets [15][16] - The company is focused on operational enhancements through strategic sourcing and better vendor management to improve efficiency and margin expansion [11][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate current market challenges, emphasizing the predictability of cash flows from existing solar assets [20][23] - The company is optimistic about achieving profitability and positive cash flow through reduced spending and operational efficiencies [31] - Management highlighted the unique position of Spruce Power as a third-party operator, which mitigates risks associated with aggressive customer acquisition strategies [23][44] Other Important Information - The company has approximately $96.5 million in total cash, with $61.9 million being unrestricted cash at the end of the first quarter [29] - The Board of Directors has approved the renewal of the company's share repurchase program [22] Q&A Session Summary Question: What is the scale of revenue opportunity for Spruce Pro and the lead times to build that business? - Management indicated that Spruce Pro is a capital-light endeavor with a deep pipeline of prospects and expects to make further announcements in the next quarter [35][36] Question: What does the refinancing environment look like for the FC1 loan? - Management expressed confidence in obtaining like-for-like terms for refinancing and is exploring more favorable credit options [38] Question: Why are SRECs for the SP Five acquisition so high compared to other assets? - Management explained that New Jersey has deep liquidity and high prices in the SREC market, which is expected to continue [39] Question: What drove the decision for the CFO transition? - Management noted that the CFO's decision to move to a private company aligns with her personal objectives, and they are actively searching for a replacement [40][41] Question: How durable is the business model compared to industry peers under the new administration? - Management highlighted that being a third-party operator allows them to mitigate risks associated with new installations and tax credits, maintaining a strong liquidity profile [43][44]

Ibotta (IBTA) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome to Ibotta's q one twenty twenty five earnings conference call. With us today are Brian Leach, founder and CEO, and Valerie Shepherd, interim CFO. Today's press release and this call may contain forward looking statements. Forward looking statements include statements about our future operating results, our guidance for Q2 twenty twenty five, our ability to grow our revenue, factors contributing to our potential ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $6.5 million, a decrease of 26% compared to Q1 2024, which included $1.4 million from discontinued clinical services [7][11] - GAAP gross margin for Q1 2025 was 46%, significantly higher than 32% in Q1 2024 [9][17] - GAAP operating expenses decreased to $11.4 million in Q1 2025 from $33.9 million in Q1 2024, primarily due to cost-saving initiatives [9][16] Business Line Data and Key Metrics Changes - The installed base of OGM systems grew to 379, a 9% year-over-year increase, with nine new installations in Q1 2025 [10] - Flow cell sales totaled 6,994 in Q1 2025, reflecting a 15% decrease year-over-year, but a 1% increase when excluding new customer sales [8][11] Market Data and Key Metrics Changes - Cash, cash equivalents, and available-for-sale securities as of March 31, 2025, were $29.2 million, with $11 million subject to restrictions [10] - The company completed a $10 million registered direct offering in January 2025 and raised net proceeds of $3.2 million through ATM sales in Q1 2025 [10] Company Strategy and Development Direction - The company has shifted its strategy to focus on existing customers who use OGM products routinely, scaling back on new instrument placements [6][7] - The strategy includes four pillars: supporting the installed base, driving utilization through software adoption, facilitating reimbursement support, and improving profitability with lower costs [7] Management's Comments on Operating Environment and Future Outlook - Management expects full-year revenues to be in the range of $26 million to $30 million, reflecting current market turbulence [17] - Q2 revenues are anticipated to be between $6.3 million and $6.8 million, with expectations to install 15 to 20 new OGM systems throughout 2025 [18] Other Important Information - The first quarter of 2025 saw 95 publications related to OGM, indicating strong engagement in research and development [13] - The company is focused on reducing cash burn and increasing gross margin, with operating expenses down 66% year-over-year [16][17] Q&A Session Summary Question: Is MD Anderson a big customer currently? - MD Anderson is an existing user and has developed a validated workflow for OGM, indicating significant adoption and impact on their operations [21][22] Question: Is the mid-40% gross margin sustainable for the remainder of the year? - Management believes the gross margin will remain stable in the mid-40% range for the rest of the year, with potential for gradual improvement [23] Question: What steps are being taken to increase SAPIRI utilization among existing routine users? - The company is focusing on training customers in using the VIA software, supporting menu expansion, and improving overall workflow proficiency [40][42]

Harley-Davidson (HOG) FY 2025 Annual General Meeting May 14, 2025 04:00 PM ET Speaker0 Noon, and welcome to the twenty twenty five annual meeting of shareholders of Harley Davidson Inc. I'm Paul Krauss, chief legal officer of the company. I'll be acting as secretary of today's meeting. Joining me today is Jochen Zeitz, chairman, president, and CEO of the company. Jochen will be the chairperson of this annual meeting. Thank you, Paul. I now call the meeting to order. At this time, I Speaker1 would like to in ...

Knightscope (KSCP) Q1 2025 Earnings Call May 14, 2025 03:00 PM ET Company Participants William Santana Li - Chairman and Chief Executive OfficerApoorv Dwivedi - EVP & CFO William Santana Li And a few things to cover. One, if you have a question, please use the q and a little button at the bottom of of the screen there for you, and we will try to answer your questions. If we can't legally answer what you're asking, we might reword your question. Another thing to note, we will not be sharing any MNPI or mater ...

Knightscope (KSCP) Q1 2025 Earnings Call May 14, 2025 03:00 PM ET Speaker0 And a few things to cover. One, if you have a question, please use the q and a little button at the bottom of of the screen there for you, and we will try to answer your questions. If we can't legally answer what you're asking, we might reword your question. Another thing to note, we will not be sharing any MNPI or material nonpublic information. We can certainly provide clarifications or stuff that's not material, but no material it ...

Financial Data and Key Metrics Changes - The company raised over $1 billion in cash through equity capital fundraising and structured finance, providing a strong financial foundation for commercialization and R&D activities [21][54][55] - The company ended the year with over $1 billion on its balance sheet, reflecting prudent financial planning [54][55] Business Line Data and Key Metrics Changes - Aficamtan is positioned as the anchor of the emerging specialty cardiology franchise, with ongoing clinical trials showing promising results [20][19] - The MAPLE HCM trial met its primary efficacy endpoint, demonstrating significant improvement in peak oxygen uptake compared to metoprolol [19][27] Market Data and Key Metrics Changes - The obstructive HCM market is now estimated to be closer to a 50/50 split with non-obstructive HCM, indicating a growing market opportunity [34] - The company aims to achieve access to over 100,000 patients in the coming years, emphasizing equitable and affordable access to its medicines [24] Company Strategy and Development Direction - The company’s Vision 02/1930 outlines a five-year strategic plan focused on innovation, access, and advancing research to benefit patients and shareholders [16][17] - The strategy includes a focus on specialty cardiology, with plans to advance multiple therapies targeting underserved patient populations [20][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the distinct benefit-risk profile of aficamtan despite the FDA extending the PDUFA date to December 2025 [18] - The company is optimistic about the potential for multiple product approvals and label expansions in the coming years [22][30] Other Important Information - The company is engaging with payers to design health economic studies and budget impact models to facilitate market access for aficamtan [42] - Partnerships with Bayer in Japan and Sanofi in China are part of the global strategy to ensure broad availability of aficamtan [43] Q&A Session Summary Question: What are the expectations for aficamtan's market entry? - The company is preparing for a potential market launch of aficamtan by the end of the year, with ongoing engagement with regulatory authorities [44][59] Question: How does the company plan to address payer concerns? - The company is designing studies to demonstrate the economic advantages of aficamtan, understanding payer motivations to ensure successful market access [42] Question: What is the significance of the recent clinical trial results? - The positive results from the MAPLE HCM trial are expected to be presented at a major medical meeting, potentially enabling expanded labeling for aficamtan [44][27]